LUNG
Pulmonx Corp

624
Mkt Cap
$78.23M
Volume
947,437.00
52W High
$9.37
52W Low
$1.47
PE Ratio
-1.34
LUNG Fundamentals
Price
$1.92
Prev Close
$1.81
Open
$1.81
50D MA
$1.70
Beta
1.28
Avg. Volume
5.5M
EPS (Annual)
-$1.44
P/B
1.13
Rev/Employee
$287,934.71
Loading...
Loading...
News
all
press releases
Pulmonx Corporation (NASDAQ:LUNG) Receives Average Recommendation of "Hold" from Analysts
Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) has received an average recommendation of "Hold" from the ten brokerages that are presently covering the company, MarketBeat.com reports. One...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
American Well Corporation (AMWL) Reports Q3 Loss, Beats Revenue Estimates
American Well (AMWL) delivered earnings and revenue surprises of +4.92% and +3.53%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
What Makes Pulmonx (LUNG) a New Buy Stock
Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
News Placeholder
After Plunging 37.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pulmonx (LUNG)
Pulmonx (LUNG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks·3mo ago
News Placeholder
Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of +5.00% and +1.25%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers
Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for severe lung disease, and the American Lung Association are continuing their ongoing collaboration...
Business Wire·1y ago
News Placeholder
Navigating 6 Analyst Ratings For Pulmonx
Latest Ratings for LUNG DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsEqual-Weight Feb 2022Wells FargoMaintainsEqual-Weight Jan 2022Morgan StanleyMaintainsEqual-Weight View More Analyst...
Benzinga·2y ago
News Placeholder
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ( Pulmonx or the "Company"), a global leader in minimally invasive treatments for lung disease, today...
Globe Newswire·2y ago
News Placeholder
Short Interest in Pulmonx Co. (NASDAQ:LUNG) Decreases By 17.5%
Pulmonx Co. (NASDAQ:LUNG - Get Free Report) saw a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 1,040,000 shares, a drop of 17.5% from...
Ticker Report·2y ago
News Placeholder
Pulmonx Co. (NASDAQ:LUNG) Given Consensus Rating of "Moderate Buy" by Analysts
Shares of Pulmonx Co. (NASDAQ:LUNG Get Free Report) have been assigned a consensus recommendation of Moderate Buy from the six ratings firms that are currently covering the...
Ticker Report·2y ago

Latest LUNG News

View

Advertisement|Remove ads.

Advertisement|Remove ads.